GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cardiovascular Systems Inc. (CSII) [hlAlert]

Rating:
Outperform
CSII
up 145.25 %

Cardiovascular Systems Inc. (CSII) rated Outperform by Leerink Swann

Posted on: Thursday,  Sep 6, 2012  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Cardiovascular Systems Inc. (NASDAQ: CSII) on 09/06/2012, when the stock price was $9.79.
Since then, Cardiovascular Systems Inc. has gained 145.25% as of 01/22/2016's recent price of $24.01.
If you would have followed this Leerink Swann 's recommendation on CSII, you would have gained 145.25% of your investment in 1233 days.

Cardiovascular Systems, Inc.(CSI) is a medical device company focused on developing and commercializing minimally invasive treatment solutions for vascular disease. The Company?s primary product, the Diamondback 360 PAD System, is a catheter-based platform capable of treating a range of plaque types in leg arteries both above and below the knee. In August 2007, the United States Food and Drug Administration (FDA) granted the Company 510(k) clearance for use of the Diamondback 360 as a therapy for treatment of patients with peripheral artery disease (PAD). As of June 30, 2009, it was selling the Diamondback 360 in 556 accounts that had completed an estimated 15,000 procedures. On February 25, 2009, Replidyne, Inc. completed its merger with Cardiovascular Systems, Inc. Pursuant to the merger, Replidyne merged with and into Cardiovascular Systems, Inc., with Cardiovascular Systems, Inc. continuing after the merger as the surviving company and a wholly owned subsidiary of Replidyne.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/6/2012 8:25 AM Buy
None
9.79
as of 12/31/2012
1 Week up  0.72 %
1 Month up  7.63 %
3 Months up  8.56 %
1 YTD up  28.19 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy